Intervention

Savolitinib

ClinicalTrials.gov intervention label

Clinical trials11

Recruiting2

Common conditions10

Lead sponsors shown8

Clinical trials

11 shown

Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.NCT06563999 · 2024-11-01

Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET OverexpressionNCT05777278 · 2023-07-26

Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLCNCT05374603 · 2022-11-15

ACTIVE_NOT_RECRUITING

Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib TreatmentNCT05261399 · 2022-08-03

ACTIVE_NOT_RECRUITING

Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLCNCT05163249 · 2022-05-31

Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLCNCT05009836 · 2021-09-06

ACTIVE_NOT_RECRUITING

Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) PatientsNCT04923945 · 2021-08-19

Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI ResistanceNCT03833440 · 2019-10-08

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)NCT03944772 · 2019-06-25

ACTIVE_NOT_RECRUITING

Prostate Cancer Biomarker Enrichment and Treatment SelectionNCT03385655 · 2018-08-01

ACTIVE_NOT_RECRUITING

A Phase II Study of HMPL-504 in Lung Sarcomatoid Carcinoma and Other Non-small Cell Lung CancerNCT02897479 · 2016-12-01

Common conditions

Non-small Cell Lung Cancer4 Carcinoma1 Carcinoma, Non-Small-Cell Lung1 Lung Cancer1 Lung Cancer Stage III1 Lung Sarcomatoid Carcinoma1 Mutation1 Non-small Cell Lung Cancer Metastatic1 Non-Small-Cell Lung1 Prostate Cancer1

Leading sponsors

AstraZeneca3 Hutchison Medipharma Limited2 Assistance Publique Hopitaux De Marseille1 Canadian Cancer Trials Group1 Guangdong Association of Clinical Trials1 Hutchmed1 Sun Yat-sen University1 The First Affiliated Hospital of Guangzhou Medical University1

Trial status mix

ACTIVE_NOT_RECRUITING5

UNKNOWN3

RECRUITING2

COMPLETED1

Phase mix

PHASE28

PHASE33

PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.